Vnitr Lek 2021, 67(4):224-229 | DOI: 10.36290/vnl.2021.057

Giant cell arteritis: controversial issues

Štefan Alušík
Katedra vnitřního lékařství, Institut postgraduálního vzdělávání ve zdravotnictví, Praha

Giant cell arteritis is the most common vasculitis in adults. The author presents the latest findings in diagnostics and treatment emphasising the growing importance of non-invasive examination methods where a biopsy of the temporal artery is no longer considered the only possible examination that confirms the diagnosis. He emphasises the importance of early diagnosis and initiation of treatment and also points out difficulties in treatment, especially frequent relapses. In addition to glucocorticoids, modern drugs influencing the decisive factors in the pathogenesis of inflammation are beginning to gain ground in treatment. Despite of new findings, there is a number of controversial issues remaining that the author addresses in more details: from terminology and epidemiology to diagnosis and treatment.

Keywords: giant cell arteritis, temporal artery biopsy, non-invasive diagnostics, glucocorticoids, tocilizumab.

Published: June 29, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Alušík Š. Giant cell arteritis: controversial issues. Vnitr Lek. 2021;67(4):224-229. doi: 10.36290/vnl.2021.057.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Jennette JC, Falk RJ, Bacon PA et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 66(1): 1-11. Go to original source... Go to PubMed...
    2. Hunder GG.The Early History of Giant Cell Arteritis and Polymyalgia Rheumatica: First Descriptions to 1970. Mayo Clin Proc. 2006; 81(8): 1071-108. Go to original source... Go to PubMed...
    3. Hutchinson J. Diseases of the arteries. Arch Surg (London) 1889/90; 1: 323-329.
    4. Horton BT, Magath TB, Brown GE. An undescribed form of arteritis of the temporal vessels. Proc Staff Meet Mayo Clin. 1932; 7: 700-701.
    5. Gilmour JR. Giant-cell chronic arteritis. J Pathol Bacteriol. 1941; 53: 263-277. Go to original source...
    6. Kilbourne ED, Wolff HG. Cranial arteritis: A critical evaluation of the syndrome of "temporal arteritis" with report of a case. Ann Intern Med 1946; 24(1): 1-10. Go to original source... Go to PubMed...
    7. Andersen T. Arteritis temporalis (Horton): a survey and a case with glaucoma. Acta Med Scand. 1947; 128: 151-178. Go to original source... Go to PubMed...
    8. McMillan GC. Diffuse granulomatous aortitis with giant cells associated with partial rupture and dissection of the aorta. AMA Arch Pathol. 1950; 49(1): 63-69.
    9. Olhagen B. Polymyalgia rheumatica: a form of senile arteritis? Acta Rheumatol Scand. 1963; 9: 157-164. Go to original source... Go to PubMed...
    10. Hamrin B, Jonsson N, Landberg T. Arteritis in "polymyalgia rheumatica." Lancet 1964; 1: 397-401. Go to original source... Go to PubMed...
    11. Alestig K, Barr J.Giant-cell arteritis. A biopsy study of polymyalgia rheumatica, including one case of Takayasu's disease. Lancet. 1963; 1(7293): 1228-1230. Go to original source... Go to PubMed...
    12. Cantini F, Niccoli L, Storri L et al. Are Polymyalgia Rheumatica and Giant Cell Arteritis the Same Disease? Semin Arthritis Rheum 2004; 33(5): 294-301. Go to original source... Go to PubMed...
    13. Kermani TA. Takayasu arteritis and giant cell arteritis: are they a spectrum of the same disease? Int J Rheum Dis 2019; 22: 41-48. Go to original source... Go to PubMed...
    14. Sharma A, Mohammad AJ, Turesson C. Incidence and prevalence of giant cell arteritis and polymyalgia rheumatica: A systematic literature review. Semin Arthritis Rheum. 2020; 50(5): 1040-1048. Go to original source... Go to PubMed...
    15. Crowson CS, Matteson EL. Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatica, 2015. Semin Arthritis Rheum. 2017; 47(2): 253-256. Go to original source... Go to PubMed...
    16. Mackie SL, Taylor JC, Haroon-Rashid L et al. Association of HLA-DRB1 amino acid residues with giant cell arteritis: genetic association study, meta-analysis and geo-epidemiological investigation. Arthritis Res Ther. 2015; 17(1): 195. Go to original source... Go to PubMed...
    17. Verdijk RM, Ouwendijk WJD, Kuijpers RWAM, Verjans GMGM. No Evidence of Varicella-Zoster Virus Infection in Temporal Artery Biopsies of Anterior Ischemic Optic Neuropathy Patients With and Without Giant Cell Arteritis. J Infect Dis. 2021; 4; 223(1): 109-112. Go to original source... Go to PubMed...
    18. Watanabe R, Goronzy JJ, Berry G, Liao YJ, Weyand CM. Giant Cell Arteritis: From Pathogenesis to Therapeutic Management. Curr Treatm Opt Rheumatol. 2016; 2(2): 126-137. Go to original source... Go to PubMed...
    19. Imai N, Kuroda R, Konishi T, Serizawa M, Kobari M. Giant cell arteritis: clinical features of patients visiting a headache clinic in Japan. Intern Med 2011; 50(16): 1679-1682. Go to original source... Go to PubMed...
    20. Mollan SP, Paemeleire K, Versijpt J et al. European Headache Federation recommendations for neurologists managing giant cell arteritis. J Headache Pain 2020; 21, 28. Go to original source... Go to PubMed...
    21. Birkhead NC, Wagener HP, Shick RM. Treatment of temporal arteritis with adrenal corticosteroids: Results in 55 cases in which the lesion was proved at biopsy. J Am Med Assoc. 1957; 163(10): 821-827. Go to original source... Go to PubMed...
    22. Singh AG, Kermani TA, Crowson CS et al. Visual manifestations in giant cell arteritis: trend over 5 decades in a population-based cohort. J Rheumatol 2015; 42: 309-315. Go to original source... Go to PubMed...
    23. Patil P, Williams M, Maw WW et al. Fast track pathway reduces sight loss in giant cell arteritis: results of a longitudinal observational cohort study. Clin Exp Rheumatol. 2015; 33 (2 Suppl 89): S-103-6.
    24. Vodopivec J, Rizzo, III.JF. Ophthalmic manifestations of giant cell arteritis, Rheumatology 2018; 57: ii63-ii72. Go to original source... Go to PubMed...
    25. Chen JJ, Leavitt JA, Fang C et al. Evaluating the Incidence of Arteritic Ischemic Optic Neuropathy and Other Causes of Vision Loss from Giant Cell Arteritis. Ophthalmology 2016; 123(9): 1999-2003. Go to original source... Go to PubMed...
    26. Peral-Cagigal B, Pérez-Villar Á, Redondo-González LM et al. Temporal headache and jaw claudication may be the key for the diagnosis of giant cell arteritis. Med Oral Patol Oral Cir Bucal. 2018;23(3): e290-e294. Go to original source... Go to PubMed...
    27. Larivière, Delphine et al. Extra-and intracranial cerebral vasculitis in giant cell arteritis: an observational study. Medicine 2014; 93(28): e265. Go to original source... Go to PubMed...
    28. Lie JT. Aortic and extracranial large vessel giant cell arteritis: a review of 72 cases with histopathologic documentation. Semin Arthritis Rheum. 1995; 24(6): 422-431. Go to original source... Go to PubMed...
    29. Nuenninghoff DM, Hunder GG, Christianson TJ et al. Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum 2003; 48: 3532-3537. Go to original source... Go to PubMed...
    30. Greigert H, Zeller M, Putot A et al. Myocardial infarction during giant cell arteritis: A cohort study. Eur. J. Intern Med 2021; 17: S0953-6205(21)00038-8. Go to original source... Go to PubMed...
    31. Zenone T. Fever of unknown origin in rheumatic diseases. Infect Dis Clin North Am. 2007; 21(4): 1115-1135, x-xi. Go to original source... Go to PubMed...
    32. Milchert M, Brzosko M. Tunnel Vision in a Patient with Polymyalgia Rheumatica. J Rheumatol. 2020; 47(1): 155-156. Go to original source... Go to PubMed...
    33. Prior JA, Ranjbar H, Belcher J et al. Diagnostic delay for giant cell arteritis - a systematic review and meta-analysis. BMC Med 2017; 15: 120. Go to original source... Go to PubMed...
    34. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990; 33: 1122-1128. Go to original source... Go to PubMed...
    35. Murchison AP, Gilbert ME, Bilyk JR et al. Validity of the American College of Rheumatology criteria for the diagnosis of giant cell arteritis. Am J Ophthalmol. 2012; 154(4): 722-729. Go to original source... Go to PubMed...
    36. van der Geest KSM, Wayel H, Abdulahad WV et al. Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica, Rheumatology 2015; 54(8): 1397-1402. Go to original source... Go to PubMed...
    37. Hellmich B, Agueda A, Monti S et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2020; 79 (1): 19-30. Go to original source... Go to PubMed...
    38. Mackie SL, Dejaco C, Appenzeller S et al. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis, Rheumatology 2020; 59(3): e1-e23. Go to original source... Go to PubMed...
    39. Chu R, Foster C, Ali M et al. Optimal length and usefulness of temporal artery biopsies in the diagnosis of giant cell arteritis: a 10- year retrospective review of medical records. Lancet Rheumatol 2020; 2(12): E 744-E 778. Go to original source...
    40. Dasgupta B. Giant Cell Arteritis Guideline Development Group. Concise guidance: diagnosis and management of giant cell arteritis. Clin Med (Lond). 2010; 10(4): 381-386. Go to original source... Go to PubMed...
    41. Stacy RC, Rizzo JF, Dean M, Cestari DM. Subtleties in the Histopathology of Giant Cell Arteritis. Seminars in Ophthalmology 2011; 26: 4-5, 342-348. Go to original source... Go to PubMed...
    42. Dejaco C, Ramiro S, Duftner C et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice Ann Rheum Dis2018; 77(5): 636-643. Go to original source... Go to PubMed...
    43. Luqmani R, Lee E, Singh S et al. The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. Health Technol Assess. 2016; 20(90): 1-238. Go to original source... Go to PubMed...
    44. Theunissen P, Kliffen M, Dees A. Giant-cell Arteritis of the Ovarian Arteries: A Rare Manifestation of a Common Disease. Eur J Case Rep Intern Med. 2018; 5(5): 000779. Go to original source... Go to PubMed...
    45. Blockmans, D. Use of FDG-PET Scan for the Assessment of Large Vessel Vasculitis. Curr Treat Options in Rheum 2016; 2: 153-160. Go to original source...
    46. Ray-Chaudhuri N, Kiné DA, Tijani SO et al. Effect of prior steroid treatment on temporal artery biopsy findings in giant cell arteritis. Br J Ophthalmol. 2002; 86(5): 530-532. Go to original source...
    47. Achkar AA, Lie JT, Hunder GG, O'Fallon WM, Gabriel SE. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med. 1994; 120(12): 987-992. Go to original source... Go to PubMed...
    48. Narváez B, Bernad D, Roig-Vilaseca C et al. Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis. Semin Arthritis Rheum 2007; 37: 13-19. Go to original source... Go to PubMed...
    49. Hellmich B, Águeda AF, Monti S et al. Treatment of Giant Cell Arteritis and Takayasu Arteritis-Current and Future. Curr Rheumatol Rep 2020; 22, 84. Go to original source... Go to PubMed...
    50. Strehl C, Bijlsma JWJ, de Wit M et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis. 2016; 75(6): 952-957. Go to original source... Go to PubMed...
    51. Ponte C, Rodrigues AF, O'Neill L, Luqmani RA. Giant cell arteritis: Current treatment and management. World J Clin Cases 2015; 3(6): 484-494. Go to original source... Go to PubMed...
    52. Koster MJ, Yeruva K, Crowson CS, Muratore F, Labarca C, Warrington KJ. Efficacy of Methotrexate in Real-world Management of Giant Cell Arteritis: A Case-control Study. J Rheumatol. 2019; 46(5): 501-508. Go to original source... Go to PubMed...
    53. Mahr AD, Jover JA, Spiera RF et al. Adjunctive Methotrexate for Treatment of Giant Cell Arteritis. An Individual Patient Data Meta-Analysis.Arth Rheum 2007; 56(8): 2789-2797. Go to original source... Go to PubMed...
    54. Stone JH, Tuckwell K, Dimonaco S et al. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017; 27; 377(4): 317-328. Go to original source... Go to PubMed...
    55. Harrington R, Al Nokhatha SA, Conway R. Biologic Therapies for Giant Cell Arteritis. Biologics. 2021; 15: 17-29. Go to original source... Go to PubMed...
    56. Sugihara T, Hasegawa H, Uchida HA et al. Associated factors of poor treatment outcomes in patients with giant cell arteritis: clinical implication of large vessel lesions. Arthritis Res Ther 2020; 22(72): 1-12. Go to original source...
    57. Maleszewski JJ, Younge BR, Fritzlen JT et al. Clinical and pathological evolution of giant cell arteritis: a prospective study of follow-up temporal artery biopsies in 40 treated patients. Mod Pathol. 2017; 30(6): 788-796. Go to original source... Go to PubMed...
    58. Nesher G, Poltorak V, Hindi I et al. Survival of patient with giant cell arteritis: Impact of vision loss and treatment with aspirin. Autoimmun Rev. 2019; 18(8): 831-834. Go to original source... Go to PubMed...
    59. Dinkin M, Johnson E. One Giant Step for Giant Cell Arteritis: Updates in Diagnosis and Treatment. Curr Treat Options Neurol 2021; 23: 6. Go to original source... Go to PubMed...
    60. Turesson C, Börjesson O, Larsson K, Mohammad AJ, Knight A. Swedish Society of Rheumatology 2018 guidelines for investigation, treatment, and follow-up of giant cell arteritis. Scand J Rheumatol. 2019; 48(4): 259-265. Go to original source... Go to PubMed...
    61. Crow RW, Katz BJ, Warner JE et al. Giant cell arteritis and mortality. J Gerontol A Biol Sci Med Sci. 2009; 64(3): 365-369. Go to original source... Go to PubMed...
    62. Hill CL, Black RJ, Nossent JC, Ruediger C, Nguyen L, Ninan JV et al. Risk of mortality in patients with giant cell arteritis: A systematic review and meta-analysis. Semin Arthritis Rheum 2017; 46: 513-519. Go to original source... Go to PubMed...
    63. Mohammad AJ, Nilsson JA, Jacobsson LT, Merkel PA, Turesson C. Incidence and mortality rates of biopsy-proven giant cell arteritis in southern Sweden. Ann Rheum Dis 2015; 74: 993-997. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.